Sana Biotechnology financials
$2.91−0.68%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — |
| Operating income | -$250.3M | -$272.7M | -$293.1M | -$272.6M | -$356.9M |
| Net income | -$244.2M | -$266.8M | -$283.3M | -$269.5M | -$355.9M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-0.96 | $-1.16 | $-1.46 | $-1.43 | $-2.14 |
| EBITDA | -$193.0M | -$255.3M | -$268.6M | -$256.9M | -$281.1M |
| Operating cash flow | -$143.8M | -$223.2M | -$253.6M | -$290.1M | -$282.9M |
| Free cash flow | -$144.8M | -$256.6M | -$273.6M | -$310.9M | -$312.8M |
| Diluted shares | 253.2M | 230.9M | 194.5M | 188.3M | 166.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $71.9M | $127.6M | $133.5M | $176.8M | $253.0M |
| Short-term investments | $66.5M | $24.9M | $71.7M | $247.2M | $298.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $416.9M | $501.0M | $565.3M | $822.7M | $1.13B |
| Total liabilities | $256.0M | $250.5M | $277.8M | $323.4M | $400.9M |
| Shareholders' equity | $160.9M | $250.5M | $287.5M | $499.3M | $728.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology